Market Overview

Boston Scientific Halted On Stryker Takeover Approach

Boston Scientific Halted On Stryker Takeover Approach
Related BSX
The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering
The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares
Boston Scientific Corp (BSX) Files –…-K for the Fiscal Year Ended on December '–, —…–8 (GuruFocus)
Related SYK
Barron's On: Where To Find Corporate Profits
62 Biggest Movers From Yesterday
What Are The Highest Quality Dividend Growth Stocks? (Seeking Alpha)

Stryker Corporation (NYSE: SYK) has approached Boston Scientific Corporation (NYSE: BSX) with a buyout opportunity, according to The Wall Street Journal.

Boston Scientific shares spiked 11 percent on the initial report and were subsequently halted with news pending. Stryker plunged 3.3 percent.

Why It’s Important

Any bid would have to surpass $40 per share, according to Stifel Nicolaus, and Wells Fargo predicted shares could be valued around $42 based on the Becton Dickinson-CR Bard deal, according to Bloomberg.

If any such merger goes through, it would be one of the biggest of 2018 given Boston Scientific’s $48-billion market cap. The resulting entity would have a combined value exceeding $110 billion.

What’s Next

Boston Scientific’s position on the prospect is yet unknown and could be announced when trading resumes.

Related Links:

No Fundamental Reason For Boston Scientific Shares' Underperformance, RBC Upgrades Stock

6 Reasons Why Needham Upgraded Boston Scientific

Photo courtesy of Boston Scientific. 

Posted-In: Bloomberg Stifel Nicolaus The Wall Street Journal Wells FargoNews M&A Best of Benzinga


Related Articles (BSX + SYK)

View Comments and Join the Discussion!

Nike's Product Line Is Tipping In A Positive Direction, According To Foot Locker

Rising Oil Prices, Apache Corp.'s Increased Permian Investment Turns Argus Bullish